Literature DB >> 15794850

Report of the Third International Workshop on Waldenstrom's macroglobulinemia.

Steven P Treon1, Pierre Morel, Veronique Leblond, Jean-Paul Fermand.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15794850     DOI： 10.3816/clm.2005.n.001

Source DB:  PubMed          Journal:  Clin Lymphoma        ISSN： 1526-9655


× No keyword cloud information.
  9 in total

1.  Pathophysiology of Waldenström's macroglobulinemia.

Authors:  Marvin J Stone; Virginia Pascual
Journal:  Haematologica       Date:  2010-03       Impact factor: 9.941

2.  Novel agents in Waldenström macroglobulinemia.

Authors:  Ghayas C Issa; Irene M Ghobrial; Aldo M Roccaro
Journal:  Clin Investig (Lond)       Date:  2011

3.  New Therapeutic Approaches for Waldenstrom Macroglobulinemia.

Authors:  Jennifer Stedman; Aldo Roccaro; Xavier Leleu; Irene M Ghobrial
Journal:  Drugs Future       Date:  2010-01       Impact factor: 0.148

4.  Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia.

Authors:  Irene M Ghobrial; Fangxin Hong; Swaminathan Padmanabhan; Ashraf Badros; Meghan Rourke; Renee Leduc; Stacey Chuma; Janet Kunsman; Diane Warren; Brianna Harris; Amy Sam; Kenneth C Anderson; Paul G Richardson; Steven P Treon; Edie Weller; Jeffrey Matous
Journal:  J Clin Oncol       Date:  2010-02-08       Impact factor: 44.544

5.  Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia.

Authors:  Irene M Ghobrial; Morie Gertz; Betsy Laplant; John Camoriano; Suzanne Hayman; Martha Lacy; Stacey Chuma; Brianna Harris; Renee Leduc; Meghan Rourke; Stephen M Ansell; Daniel Deangelo; Angela Dispenzieri; Leif Bergsagel; Craig Reeder; Kenneth C Anderson; Paul G Richardson; Steven P Treon; Thomas E Witzig
Journal:  J Clin Oncol       Date:  2010-02-08       Impact factor: 44.544

6.  Novel agents in Waldenstrom Macroglobulinemia.

Authors:  Antonio Sacco; Xavier Leleu; Giuseppe Rossi; Irene M Ghobrial; Aldo M Roccaro
Journal:  Open J Hematol       Date:  2010-05-28

7.  Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia.

Authors:  Irene M Ghobrial; Aldo Roccaro; Fangxin Hong; Edie Weller; Nancy Rubin; Renee Leduc; Meghan Rourke; Stacey Chuma; Antonio Sacco; Xiaoying Jia; Feda Azab; Abdel Kareem Azab; Scott Rodig; Diane Warren; Brianna Harris; Lyuba Varticovski; Peter Sportelli; Xavier Leleu; Kenneth C Anderson; Paul G Richardson
Journal:  Clin Cancer Res       Date:  2010-01-26       Impact factor: 12.531

8.  A Diagnostic Dilemma: Waldenström's Macroglobulinemia/Plasma Cell Leukemia.

Authors:  Bhawna Sethi; K S Butola; Yogesh Kumar
Journal:  Case Rep Pathol       Date:  2012-09-09

9.  MYD88 L265P mutations are correlated with 6q deletion in Korean patients with Waldenström macroglobulinemia.

Authors:  Jung-Ah Kim; Kyongok Im; Si Nae Park; Jiseok Kwon; Qute Choi; Sang Mee Hwang; Naohiro Sekiguchi; Sung-Soo Yoon; Dong Soon Lee; Seon Young Kim
Journal:  Biomed Res Int       Date:  2014-05-07       Impact factor: 3.411
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.